Home Cart Sign in  
Chemical Structure| 29767-20-2 Chemical Structure| 29767-20-2

Structure of Teniposide
CAS No.: 29767-20-2

Chemical Structure| 29767-20-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Teniposide, a derivative of podophyllotoxin, can interact with DNA topoisomerase II and is used in cancer medicine.

Synonyms: VM26; NSC 122819; HSDB 6546

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Teniposide

CAS No. :29767-20-2
Formula : C32H32O13S
M.W : 656.65
SMILES Code : O=C1OC[C@]2([H])[C@H](O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO4)O3)O[C@@H]4C5=CC=CS5)O)O)C6=C(C=C7OCOC7=C6)[C@@H](C8=CC(OC)=C(O)C(OC)=C8)[C@]21[H]
Synonyms :
VM26; NSC 122819; HSDB 6546
MDL No. :MFCD00866516
InChI Key :NRUKOCRGYNPUPR-QBPJDGROSA-N
Pubchem ID :452548

Safety of Teniposide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H351-H361
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Teniposide

DNA

Isoform Comparison

Biological Activity

Target
  • Topo II

In Vitro:

Cell Line
Concentration Treated Time Description References
MDA-MB-231 500 nM 24 hours To assess the effect of Teniposide on cell viability, results showed minimal impact on cell viability at low concentrations. PMC11079014
Glioblastoma stem-like cells (GSCs) 0.5 µM 24 hours To evaluate the cytotoxic effect of Teniposide on GSCs under normoxic and hypoxic conditions. Results showed that Teniposide decreased GSC viability under normoxia but no changes were observed under hypoxia, indicating hypoxia enhances chemoresistance of GSCs to Teniposide. PMC9409164
MDA-MB-231-1833 500 nM 5 days To evaluate the effect of Teniposide on 3D growth morphology, results showed Teniposide significantly reduced invasive growth morphology. PMC11079014

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice CT26 tumor model Intraperitoneal injection 10 mg/kg Once on day 6 and once on day 7 To evaluate the inhibitory effect of Teniposide on tumor growth and its impact on immune cell infiltration in the tumor microenvironment. Results showed that Teniposide significantly inhibited tumor growth and increased the number and activity of tumor-infiltrating CD8+ T cells. PMC6819145
C57BL/6J mice Hepa1-6 liver orthotopic tumor model Intraperitoneal injection 10 mg/kg Twice, interval not specified Evaluate the effect of HBO combined with teniposide treatment on the efficacy of PD-1 antibody. Results showed that HBO significantly enhanced teniposide-induced cGAS-STING-dependent tumor type I interferon and NF-κB signaling, both of which contributed to the activation of dendritic cells and subsequent cytotoxic T cells. PMC9413187
Nude mice Breast cancer lung metastasis model Tail vein injection 500 nM Single injection, observed for 21 days To assess the effect of Teniposide on breast cancer lung metastasis, results showed Teniposide significantly reduced the formation of lung metastatic colonies. PMC11079014

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00198991 Adult Acute Lymphocytic Leukem... More >>ia Less << Phase 4 Unknown - Germany ... More >> University of Frankfurt, Medical Dept. II Recruiting Frankfurt, Germany, 60590 Contact: Dieter Hoelzer, MD,PhD    ++49(0)69 6301 5194    hoelzer@em.uni-frankfurt.de    Contact: Nicola Goekbuget, MD    ++49(0)69 6301 6365    goekbuget@em.uni-frankfurt.de    Principal Investigator: Dieter Hoelzer, MD,PhD          Sub-Investigator: Nicola Goekbuget, MD Less <<
NCT02086942 Multiple Myeloma Phase 2 Recruiting August 2017 China, Jiangsu ... More >> Jinling Hospital Recruiting Nanjing, Jiangsu, China, 210002 Contact: zhai yo ping, doctor    13951947646    ypzhai@medmail.com.cn Less <<
NCT00199004 Adult Acute Lymphocytic Leukem... More >>ia Less << Phase 4 Completed - Germany ... More >> University Hospital of Frankfurt, Medical Dept. II Frankfurt, Germany, 60590 Less <<
NCT00199056 Adult Acute Lymphocytic Leukem... More >>ia Less << Phase 4 Completed - Germany ... More >> University Hospital, Medical Dept. II Frankfurt, Germany, 60590 Less <<
NCT00199095 Adult Acute Lymphocytic Leukem... More >>ia Less << Phase 4 Completed - Germany ... More >> University Hospital, Medical Dept. II Frankfurt, Germany, 60590 Less <<
NCT00002531 Leukemia Phase 2 Unknown - Germany ... More >> Klinikum der J.W. Goethe Universitaet Frankfurt, Germany, D-60590 Less <<
NCT02645864 Esophageal Squamous Cell Carci... More >>noma Less << Phase 1 Recruiting December 2017 China, Beijing ... More >> Peking University Cancer Hospital Recruiting Beijing, Beijing, China, 100142 Contact: Xiaodong Zhang    86-10-88196961    zxd0829@hotmail.com    Principal Investigator: Xiaodong Zhang Less <<
NCT00187083 Acute Lymphoblastic Leukemia Phase 3 Completed - United States, Tennessee ... More >> St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 Less <<
NCT00343369 Leukemia Not Applicable Unknown - Germany ... More >> Evangelisches Krankenhauus Bielfeld Recruiting Biefeld, Germany, 33617 Contact: N. Jorch, MD    49-52-177-278-050       Klinikum Bremen-Mitte Recruiting Bremen, Germany, D-28205 Contact: Arnulf Pekrun, MD, PhD    49-421-497-3656    arnulf.pekrun@klinikum-bremen-mitte.de    Universitaetsklinikum Duesseldorf Recruiting Duesseldorf, Germany, D-40225 Contact: Contact Person    49-211-311-7990       Universitats - Kinderklinik Recruiting Greiswald, Germany, 17487 Contact: James F. Beck, MD    49-383-486-6325    beck@uni-greifswald.de    University Medical Center Hamburg - Eppendorf Recruiting Hamburg, Germany, D-20246 Contact: Gritta Janka-Schaub    49-404-2803-2580       Kreskrankenhaus Kinderabteilung Recruiting Heide, Germany, 25746 Contact: Streitberger    49-481-785-911       Clinic for Bone Marrow Transplantation and Hematology and Oncology Recruiting Idar-Oberstein, Germany, D-55743 Contact: Wenzel Nuernberger, MD, PhD    49-6781-66-1582    wnuernberger@bmt-center-io.com    Klinikum Krefeld GmbH Recruiting Krefeld, Germany, D-47805 Contact: P. Thomas    49-2151-322-375       Universitaets - Kinderklinik Recruiting Leipzig, Germany, D-04317 Contact: Dieter Koerholz, MD    49-341-9726-246    koerd@medizin.uni-leipzig.de    Johannes Gutenberg University Recruiting Mainz, Germany, D-55101 Contact: P. Gutjahr, MD    49-6131-17-2112       Krankenhaus Neuwerk Klinik fuer Kinder und Jugendmedizin Recruiting Moenchengladbach, Germany, D-41066 Contact: Wolfgang Mueller, MD    49-2161-668-2481       Dr. von Haunersches Kinderspital der Universitaet Muenchen Recruiting Munich, Germany, D-80337 Contact: Arndt Borkhardt    49-89-5160-4498       Staedtisches Krankenhaus Muenchen - Harlaching Recruiting Munich, Germany, D-81545 Contact: Papucek    49-89-6210-2710       Klinik St. Hedwig-Kinderklinik Recruiting Regensburg, Germany, 93049 Contact: Ove Peters    49-941-369-5404       Dr. Horst-Schmidt-Kliniken Recruiting Wiesbaden, Germany, D-65199 Contact: Gerhard Beron, MD    49-611-43-2564       Helios Kliniken Wuppertal University Hospital Recruiting Wuppertal, Germany, D-42283 Contact: B. Dohrn, MD    49-202-896-3823    bdohrn@wuppertal.helios-klinikum.de Less <<
NCT00199069 Adult Acute Lymphocytic Leukem... More >>ia Less << Phase 4 Completed - Germany ... More >> University Hospital, Medical Dept. II Frankfurt, Germany Less <<
NCT02788201 Urothelial Carcinoma ... More >> Bladder Cancer Urinary Bladder Neoplasms Less << Phase 2 Recruiting July 1, 2020 United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    888-624-1937 Less <<
NCT01290120 Burkitt Lymphoma ... More >> B-ALL Less << Phase 2 Completed - Italy ... More >> Divisione di Ematologia e TMO, Ospedale San Maurizio Bolzano, (bz), Italy Ematologia e centro TMO - Ospedale Armando Businco Cagliari, (ca), Italy S.C. Ematologia - Azienda Ospedaliera S. Croce e Carle Cuneo, (cn), Italy Onco-Ematologia - Ospedale Civile Noale, (ve), Italy Dipartimento di Ematologia e Medicina Trasfusionale - Azienda Osp. Nazionale Santi Antonio e Biagio e Cesare Arrigo Alessandria, AL, Italy USC Ematologia Ospedali Riuniti di Bergamo Bergamo, BG, Italy Divisione Ematologia Spedali Civili Brescia, BS, Italy, 25123 Ematologia - AOU Careggi Firenze, FI, Italy Ematologia e TMO - Ospedale San Raffaele Milano, MI, Italy Ematologia - TMO - Ospedale San Gerardo Monza, MI, Italy Ematologia Ospedale San Bortolo Vicenza, VI, Italy, 36100 USC Ematologia Ospedali Riuniti di Bergamo Bergamo, Italy, 24128 Less <<
NCT02290132 - Unknown July 2017 China, Shanghai ... More >> Shanghai First People's HOSPITAL Recruiting Shanghai, Shanghai, China, 200127 Contact: YANG JUN, master    13564880726    yangjuan74@hotmail.com    Contact: wang chun, doctor    13386259777    wangchun2@medmail.com.cn Less <<
NCT00004231 Lymphoma Phase 2 Completed - United States, Illinois ... More >> Robert H. Lurie Comprehensive Cancer Center at Northwestern University Chicago, Illinois, United States, 60611 Less <<
NCT01430013 T Cell Lymphoma Phase 2 Unknown December 2015 China, Tianjin ... More >> Tianjin Medical University Cancer Institute and Hospital Tianjin, Tianjin, China, 300060 Less <<
NCT00853008 Acute Lymphoblastic Leukemia Phase 4 Active, not recruiting January 2019 Spain ... More >> Hospital General Alicante, Spain Hospital Germans Trias i Pujol Badalona, Spain Clínica Teknon Barcelona, Spain Hospital Clínic i Provincial Barcelona, Spain Hospital de Sant Pau Barcelona, Spain Hospital Duran y Reynals Barcelona, Spain Hospital Vall d'Hebrón Barcelona, Spain Hospital General Castellón, Spain Hospital San Pedro de Alcántara Cáceres, Spain Hospital Puerta del Mar Cádiz, Spain Hospital Josep Trueta Girona, Spain Hospital Universitario Guadalajara, Spain Hospital Juan Canalejo La Coruña, Spain Hospital Xeral Lugo, Spain Hospital 12 de Octubre Madrid, Spain Hospital Clínico Universitario Madrid, Spain Hospital de Fuenlabrada Madrid, Spain Hospital Ramón y Cajal Madrid, Spain Hospital Morales Messeguer Murcia, Spain Hospital Carlos Haya Málaga, Spain Hospital Virgen de la Victoria Málaga, Spain Hospital Central de Asturias Oviedo, Spain Hospital Son Llàtzer Palma de Mallorca, Spain Clínica Universitaria de Navarra Pamplona, Spain Hospital Parc Taulí Sabadell, Spain Hospital Clínico Universitario Salamanca, Spain Hospital Marqués de Valdecilla Santander, Spain Hospital Xeral Santiago, Spain Hospital Virgen del Rocio Sevilla, Spain Hospital Joan XXIII Tarragona, Spain Hospital Mútua de Terrassa Terrassa, Spain Hospital Clínico Universitario Valencia, Spain Hospital Dr Pesset Valencia, Spain Hospital General Valencia, Spain Hospital La Fe Valencia, Spain Hospital Clínico Valladolid, Spain Hospital Virgen de la Concha Zamora, Spain Hospital Lozano Blesa Zaragoza, Spain Less <<
NCT02028650 - Completed - China, Beijing ... More >> Affiliated Hospital of Academy of Military Medical Sciences Beijing, Beijing, China, 100071 Less <<
NCT00696735 Follicular Lymphoma Phase 3 Completed - France ... More >> Emmanuel GYAN Tours, France, 37000 Philippe COLOMBAT Tours, France, 37000 Less <<
NCT00184041 Acute Lymphoblastic Leukemia Phase 2 Completed - United States, California ... More >> USC/Norris Comprehensive Cancer Center and Hospital Los Angeles, California, United States, 90032 Less <<
NCT01700946 Recurrent B-Cell Childhood Acu... More >>te Lymphoblastic Leukemia Recurrent Childhood B-Lymphoblastic Lymphoma Less << Phase 2 Recruiting October 2021 United States, California ... More >> Rady Children's Hospital and Health Center Completed San Diego, California, United States, 92123 United States, Tennessee St. Jude Children's Research Hospital Recruiting Memphis, Tennessee, United States, 38105 Contact: Sima Jeha, MD    866-278-5833    referralinfo@stjude.org    Principal Investigator: Sima Jeha, MD          United States, Texas Cook Children's Medical Center Recruiting Fort Worth, Texas, United States, 76104 Contact: Kenneth M. Heym, MD    682-885-4007       Principal Investigator: Kenneth M. Heym, MD Less <<
NCT00186875 Acute Lymphoblastic Leukemia ... More >> Lymphoma, Lymphoblastic Less << Phase 2 Completed - United States, California ... More >> Rady Children's Hospital and Health Center San Diego, California, United States, 92123 United States, Tennessee St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 Less <<
NCT00186875 - Completed - -
NCT01960192 Primary CNS Lymphoma (PCNSL) Phase 4 Recruiting June 2020 China, Henan ... More >> Oncology Department of The First Affiliated Hospital of Zhengzhou University Recruiting Zhengzhou, Henan, China, 450052 Contact: Mingzhi Zhang, Pro,Dr    13838565629    mingzhi_zhang@126.com Less <<
NCT00004916 Lymphoma Phase 1 Phase 2 Completed - United States, Illinois ... More >> Robert H. Lurie Comprehensive Cancer Center, Northwestern University Chicago, Illinois, United States, 60611-3013 Less <<
NCT06048107 HLH RECRUITING 2025-09-30 Zhao Wang, Beijing, 100050, Ch... More >>ina, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.52mL

0.30mL

0.15mL

7.61mL

1.52mL

0.76mL

15.23mL

3.05mL

1.52mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories